These findings suggest a modest benefit of addition of either PARPi or bevacizumab to PD-1/PD-L1 blockade in germline BRCA wild-type ovarian cancer patients, warranting further investigation of our 3-drug combination strategy. The gene discussed is CD274; the disease is ovarian carcinoma.